27th April 2010 - News release

In April 2008, Neupro was withdrawn from use in the U.S.A. because specific batches of Neupro had deviated from their specification. Neupro (Rotigotine) is a dopamine agonist used with Parkinson's Disease that, via a skin patch, provides a slow and constant supply of Rotigotine over the course of 24 hours. For more information go to Neupro. The FDA have informed the manufacturers UCB that Neupro must be reformulated before it can be made available
again in the U.S.A.. This means that Neupro could be withdrawn from use for another two years. In June 2009, UCB proposed new refrigerated storage conditions to alleviate crystallization on the patches. The FDA "agrees that the proposed new refrigeration conditions significantly inhibit the degree of crystallization on the patches, but has recommended that the definitive resolution of the crystallization is to reformulate the drug product". This FDA decision does not impact product supply and availability in Europe and the rest of the world. For more information go to the complete News release For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports





2006-2010  Viartis
2015-11-09 21:58:48
[email protected]